针对白血病中的Tudor域:用于药物开发的表观遗传见解
Aditi Pedgaonkar1, Neha Niranjan1, Aniruddha J Deshpande1
1Cancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Epigenomics
|July 7, 2025
概括
图多域蛋白质通过调节基因表达和DNA修复,对白血病的发展至关重要. 准这些表观遗传调节器为治疗白血病和克服耐药性提供了一个有希望的新策略.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 白血病涉及由于表观遗传变化的血细胞不受控制的生长.
- 染色体相互作用蛋白质,包括Tudor域蛋白质,是白血病发生的关键驱动因素.
- 异常的表观遗传调节是白血病进展的标志.
研究的目的:
- 审查Tudor域含有蛋白质在白血病中的结构和功能作用.
- 探索针对Tudor域在白血病治疗中的治疗潜力.
- 强调白血病表观遗传失调的重要性和潜在的治疗策略.
主要方法:
- 结构分析各种Tudor域及其基因组修饰结合偏好.
- 关于特异性图多域蛋白 (SGF29,JMJD2A,53BP1,Spindlin1,UHRF1) 在白血病中的作用的文献综述.
- 对Tudor领域的药理学向策略的检查.
主要成果:
- 图多域蛋白调节关键过程,如DNA损伤反应,转录调节和白血病中的RNA代谢.
- 特定的Tudor域表现出明显的结合偏好,用于组织蛋白修饰,影响白血病细胞的行为.
- 对Tudor域的药理定位为白血病提供了一个新的治疗途径.
结论:
- 图多域蛋白在白血病进展中至关重要,使它们成为有吸引力的治疗点.
- 通过Tudor域抑制向表观遗传失调,对白血病治疗具有重大前景.
- 进一步研究基于表观遗传学的策略对于打击白血病耐药性和复发至关重要.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K


